Comprehensive Forecast: Congenital Diaphragmatic Hernia Drugs Market Share, Growth, and Opportunities Through 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Forecasted Growth Rate and Market Size of the Congenital Diaphragmatic Hernia Drugs Market?
The market size for drugs treating congenital diaphragmatic hernia has seen impressive growth in the past few years. The industry, valued at $4.38 billion in 2024, is forecasted to rise to $4.69 billion in 2025. This predicts an annual compound growth rate (CAGR) of 7.0%. Factors contributing to this growth during the historic period include an increased prevalence of congenital diaphragmatic hernia cases, raising consciousness about the disease, and government initiatives.
The market for drugs treating congenital diaphragmatic hernia is predicted to experience substantial expansion in the coming years. It is anticipated to reach “$6.25 billion in 2029 with a compound annual growth rate (CAGR) of 7.4%” Factors contributing to growth during this projected period include increased health care spending, incentives for rare diseases, a rise in patient advocacy groups, regenerative medicine, and targeted therapies. The period will also see key trends such as progress in medical research, drug development advancements, improvements in fetal surgery, growth in pharmacological lung, growing preference for personalized medicine, the innovation of novel drug delivery systems and emergent digital health technologies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12928&type=smp
Which Factor Is Shaping The Future Of The Congenital Diaphragmatic Hernia Drugs Market?
The escalating rate of birth defects is anticipated to fuel the expansion of the congenital diaphragmatic hernia drug market. Birth defects constitute functional or structural anomalies present at birth, potentially impinging on an infant’s health and developmental trajectory. The medical response to congenital diaphragmatic hernia incorporates prenatal screening, genetic advice, and specialized therapies. These help decrease birth defect incidents related to congenital diaphragmatic hernia, offering opportunities for early intervention and personalized care, thereby boosting the general wellness and life quality of those affected. For example, in March 2023, the World Health Organization (WHO), an intergovernmental organization based in the US, reported that every year roughly 8 million babies are born with birth defects, with the greater share of serious issues, 9 in 10, being in low to middle-income countries. Moreover, estimates suggest that around 240,000 newborns globally die within the first 28 days of their life due to congenital disorders annually. As such, the growing rate of birth defects influences the growth of the congenital diaphragmatic hernia drug market positively.
The congenital diaphragmatic hernia drugs market covered in this report is segmented –
1) By Type: Posterolateral Bochdalek Hernia, Anterior Morgagni Hernia, Hiatal Hernia
2) By Treatment: Extracorporeal Membrane Oxygenation, Other Treatments
3) By Diagnosis: Prenatal, Postnatal
4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Posterolateral Bochdalek Hernia: Surgical Interventions, Medications for Symptoms
2) By Anterior Morgagni Hernia: Surgical Interventions, Medications for Symptoms
3) By Hiatal Hernia: Surgical Interventions, Medications
How Are Key Trends Driving Expansion In The Congenital Diaphragmatic Hernia Drugs Industry?
Leading firms in the congenital diaphragmatic hernia (CDH) market are utilizing coating technology to innovate treatment procedures and maintain their market dominance. This technology, applied to drug-embedded synthetic hernia mesh, involves a specialized layer or coating on the mesh’s surface used for hernia repair. For example, Ariste Medical, an American pre-commercial drug and device firm, was granted approval from the U.S. Food and Drug Administration (FDA) in April 2022 to sell its drug-embedded synthetic hernia mesh. The mesh aims to decrease microbial colonization risk during surgical implantation by combining polypropylene mesh benefits with a biocompatible coating that fosters antibiotic residence to lessen bacterial colonization. This coating technology, applicable to both implantable and non-implantable devices, has shown promise in materials such as polyurethane and ePTFE. Furthermore, Ariste Medical’s coating technology could potentially be applied to ePTFE surgical implants used in hernia repair surgeries.
Which Companies Hold The Largest Market Share In The Congenital Diaphragmatic Hernia Drugs Sector?
Major companies operating in the congenital diaphragmatic hernia drugs market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Novartis AG, GlaxoSmithKline PLC, Medtronic PLC, Amgen Inc., Becton, Dickinson and Company, Viatris Inc., B. Braun SE, Sun Pharmaceutical Industries Ltd., C.R. Bard Inc., W. L. Gore & Associates, Chiesi Farmaceutici S.p.A., Getinge AB, Ferring Pharmaceuticals, Mallinckrodt Pharmaceuticals, Integra LifeSciences Corporation, Genentech Inc., LifeCell International Private Limited, Cook Biotech Inc., Cousin Biotech SAS, Dipro Medical Devices S.R.L., Aspide Medical.
How Does Regional Performance Compare Across The Congenital Diaphragmatic Hernia Drugs Industry?
North America was the largest region in the congenital diaphragmatic hernia drugs market in 2024. The regions covered in congenital diaphragmatic hernia drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12928&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
